Integrated genomic and epigenomic analysis of circulating tumor DNA from patients with BRAF V600-mutant melanoma - COSMOS-MEL-02

ational Cancer Center Hospital East0 个研究点目标入组 50 人开始时间: 2023年7月20日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. A history of active malignancy within 5 years of disease-free status. However, patients with basal cell carcinoma or squamous cell carcinoma of the skin, superficial bladder cancer, cervical cancer, endoscopically curable carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma equivalent lesions, or non-metastatic prostate cancer that does not require systemic treatment, who are judged to be cured by local treatment, will be enrolled in the registry if they are disease-free for 5 years or less It shall be possible. 2. Duplicate cancers are suspected on the head, neck, thorax, abdomen, and pelvic contrast CT scan within 84 days before enrollment *1*2. 3. Women who are pregnant or breastfeeding 4. Attending physician determines that the subject is unsuitable for enrollment in this study. *1 Subjects with allergies/sensitivities to contrast media, etc. may be performed without contrast media. *2 Contrast brain CT can be replaced with brain MRI.

发起方

ational Cancer Center Hospital East